Axovant Sciences (AXON) says Lunbeck study failure was expected - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Doctors Say Yearly Memory Evaluations are Critical to Early Diagnosis, Effective Treatment of Alzheimer's Disease
September 21, 2016 8:03 AM EDTNEW YORK, Sept. 21, 2016 /PRNewswire/ -- Memory evaluations are critical to the early diagnosis and effective treatment of people with Alzheimer's disease, according to Dr. Gary Small, director of geriatric psychiatry at UCLA's Semel Institute for Neuroscience and Human Behavior.
While more than 5 million Americans currently have Alzheimer's disease, less than half are diagnosed1.
"A simple memory evaluation is a critical first step toward addressing dementia in its earliest stages," said Dr. Small, who is also a member of the... More
